VBI Vaccines, Inc.
(NASDAQ : VBIV)

( )
VBIV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.76%61.120.0%$946.54m
GILDGilead Sciences, Inc. 0.39%76.361.0%$771.76m
AMGNAmgen, Inc. -0.83%253.011.3%$742.65m
REGNRegeneron Pharmaceuticals, Inc. 0.29%610.952.5%$680.54m
NVAXNovavax, Inc. -2.26%77.90102.0%$593.23m
BIIBBiogen, Inc. 0.00%264.771.6%$543.38m
VRTXVertex Pharmaceuticals, Inc. -0.09%286.031.9%$523.72m
ILMNIllumina, Inc. -0.49%368.553.5%$308.59m
ALXNAlexion Pharmaceuticals, Inc. 0.13%112.392.0%$229.11m
BMRNBioMarin Pharmaceutical, Inc. 0.71%126.734.3%$216.24m
SGENSeattle Genetics, Inc. -0.19%167.206.1%$201.47m
SRNESorrento Therapeutics, Inc. 1.15%7.011.8%$189.08m
SRPTSarepta Therapeutics, Inc. 1.40%168.0013.9%$171.02m
INCYIncyte Corp. 0.73%103.402.5%$161.17m
IMMUImmunomedics, Inc. 0.27%37.0111.0%$154.74m

Company Profile

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.